Ticker
ALBO

Price
23.78
Stock movement up
+0.84 (3.66%)
Company name
Albireo Pharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
465.52M
Ent verdi
361.94M
Pris/omsetning
10.24
Pris/bok
3.14
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
0.98%
3 års avkastning
4.31%
5 års avkastning
-1.01%
10 års avkastning
-11.10%
Sist oppdatert: 2022-12-05

UTBYTTE

ALBO betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning10.24
Pris til bok3.14
EV i forhold til salg7.96

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall19.58M
EPS (TTM)-1.70
FCF per aksje (TTM)-5.66

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)45.45M
Bruttofortjeneste (TTM)43.85M
Driftsinntekter (TTM)-123.27M
Netto inntekt (TTM)-32.73M
EPS (TTM)-1.70
EPS (1 år fremover)-3.67

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)96.50%
Driftsmargin (TTM)-271.24%
Fortjenestemargin (TTM)-72.02%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter216.66M
Netto fordringer1.27M
Samlede omløpsmidler228.73M
Goodwill17.26M
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler261.26M
Leverandørgjeld6.37M
Kortsiktig/nåværende langsiktig gjeld10.08M
Sum kortsiktig gjeld31.51M
Sum gjeld113.08M
Aksjonærenes egenkapital148.19M
Netto varige driftsmidler130.93M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-108.25M
Kapitalutgifter (TTM)979.00K
Fri kontantstrøm (TTM)-109.23M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-22.09%
Avkastning på eiendeler-12.53%
Avkastning på investert kapital-22.09%
Kontantavkastning på investert kapital-73.71%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning22.70
Daglig høy24.00
Daglig lav22.45
Daglig volum147K
Tidenes høyeste2995.20
1 år analytikerestimat70.40
Beta0.93
EPS (TTM)-1.70
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon27 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ALBOS&P500
Nåværende prisfall fra toppnotering-99.21%-14.82%
Høyeste prisfall-99.77%-56.47%
Dato for høyeste fall17 Dec 20159 Mar 2009
Gj.snittlig fall fra topp-89.94%-11.46%
Gj.snittlig tid til ny topp261 days13 days
Maks tid til ny topp3751 days1805 days
SELSKAPSOPPLYSNINGER
ALBO (Albireo Pharma Inc) company logo
Markedsverdi
465.52M
Markedsverdi kategori
Small-cap
Beskrivelse
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Ansatte
130
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Ronald H. W. Cooper
Land
USA
By
Boston
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced...
30. november 2022
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...
10. november 2022
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced...
9. november 2022
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
8. november 2022
Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD P...
8. november 2022
Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and increa...
7. november 2022
— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in the lives of PFIC patients BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Albireo P...
3. november 2022
– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On track to report topline data by the end of 2024, reinforcing Bylvay's expected posit...
2. november 2022
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1. november 2022
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC – Analysis of PEDFIC 1 data sh...
1. november 2022
Neste side